CN103083297A - 丹酚酸a组合物用于制备改善脑缺血后的神经功能症状药物的用途 - Google Patents
丹酚酸a组合物用于制备改善脑缺血后的神经功能症状药物的用途 Download PDFInfo
- Publication number
- CN103083297A CN103083297A CN2012104891218A CN201210489121A CN103083297A CN 103083297 A CN103083297 A CN 103083297A CN 2012104891218 A CN2012104891218 A CN 2012104891218A CN 201210489121 A CN201210489121 A CN 201210489121A CN 103083297 A CN103083297 A CN 103083297A
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- acid
- compositions
- group
- cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 title claims abstract description 628
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 title claims abstract description 627
- 239000000203 mixture Substances 0.000 title claims abstract description 364
- 206010008118 cerebral infarction Diseases 0.000 title claims abstract description 103
- 201000006474 Brain Ischemia Diseases 0.000 title claims abstract description 84
- 206010008120 Cerebral ischaemia Diseases 0.000 title claims abstract description 83
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 208000024891 symptom Diseases 0.000 title abstract description 12
- 230000001537 neural effect Effects 0.000 title abstract description 7
- 229940079593 drug Drugs 0.000 title abstract description 6
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims abstract description 113
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims abstract description 112
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims abstract description 112
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims abstract description 84
- 239000002253 acid Substances 0.000 claims abstract description 51
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims abstract description 42
- GCJWPRRNLSHTRY-UHFFFAOYSA-N Salvianolic acid C Natural products C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)=CC=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-UHFFFAOYSA-N 0.000 claims abstract description 42
- GCJWPRRNLSHTRY-VURDRKPISA-N Salvianolic acid C Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2C=C(OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-VURDRKPISA-N 0.000 claims abstract description 42
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims abstract description 42
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims abstract description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 299
- 239000000243 solution Substances 0.000 claims description 111
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 93
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 87
- 239000000284 extract Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 56
- 238000010828 elution Methods 0.000 claims description 48
- 238000000605 extraction Methods 0.000 claims description 46
- 239000011347 resin Substances 0.000 claims description 46
- 229920005989 resin Polymers 0.000 claims description 46
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 44
- 239000007864 aqueous solution Substances 0.000 claims description 43
- 239000013558 reference substance Substances 0.000 claims description 39
- 238000003756 stirring Methods 0.000 claims description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- 239000003054 catalyst Substances 0.000 claims description 32
- 238000012360 testing method Methods 0.000 claims description 32
- 230000001476 alcoholic effect Effects 0.000 claims description 30
- 230000006837 decompression Effects 0.000 claims description 30
- 238000004064 recycling Methods 0.000 claims description 30
- 239000007924 injection Substances 0.000 claims description 29
- 238000002347 injection Methods 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 29
- 239000003480 eluent Substances 0.000 claims description 26
- 239000012535 impurity Substances 0.000 claims description 26
- 238000001291 vacuum drying Methods 0.000 claims description 26
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 24
- 239000000796 flavoring agent Substances 0.000 claims description 23
- 235000019634 flavors Nutrition 0.000 claims description 23
- 230000002829 reductive effect Effects 0.000 claims description 23
- 239000006228 supernatant Substances 0.000 claims description 23
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 22
- 235000017276 Salvia Nutrition 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 20
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 14
- 238000000746 purification Methods 0.000 claims description 14
- 239000004952 Polyamide Substances 0.000 claims description 13
- 239000012071 phase Substances 0.000 claims description 13
- 229920002647 polyamide Polymers 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- 238000004440 column chromatography Methods 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 11
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- 238000003809 water extraction Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 7
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 6
- 238000004811 liquid chromatography Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000001117 sulphuric acid Substances 0.000 claims description 6
- 235000011149 sulphuric acid Nutrition 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 208000020470 nervous system symptom Diseases 0.000 claims description 5
- 238000010898 silica gel chromatography Methods 0.000 claims description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 4
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
- 239000012074 organic phase Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 238000000638 solvent extraction Methods 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 2
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 241001072909 Salvia Species 0.000 claims 2
- 241000700159 Rattus Species 0.000 description 260
- 230000002490 cerebral effect Effects 0.000 description 197
- 210000001519 tissue Anatomy 0.000 description 178
- 208000028867 ischemia Diseases 0.000 description 120
- 230000000694 effects Effects 0.000 description 114
- 150000001875 compounds Chemical class 0.000 description 112
- 210000004556 brain Anatomy 0.000 description 87
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 85
- 230000000302 ischemic effect Effects 0.000 description 62
- 206010021143 Hypoxia Diseases 0.000 description 56
- 230000006378 damage Effects 0.000 description 53
- 208000007536 Thrombosis Diseases 0.000 description 51
- 206010008132 Cerebral thrombosis Diseases 0.000 description 41
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 41
- 229960000715 nimodipine Drugs 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 40
- 239000000741 silica gel Substances 0.000 description 38
- 229910002027 silica gel Inorganic materials 0.000 description 38
- 229960001866 silicon dioxide Drugs 0.000 description 38
- 230000010410 reperfusion Effects 0.000 description 37
- 239000000523 sample Substances 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 33
- 208000027418 Wounds and injury Diseases 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- 230000007954 hypoxia Effects 0.000 description 31
- 208000014674 injury Diseases 0.000 description 31
- 230000006907 apoptotic process Effects 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 28
- 208000005189 Embolism Diseases 0.000 description 27
- 210000004204 blood vessel Anatomy 0.000 description 27
- 239000011575 calcium Substances 0.000 description 27
- 210000002569 neuron Anatomy 0.000 description 26
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 24
- 230000006870 function Effects 0.000 description 24
- 206010063837 Reperfusion injury Diseases 0.000 description 23
- 210000005013 brain tissue Anatomy 0.000 description 23
- 210000003462 vein Anatomy 0.000 description 23
- 206010061216 Infarction Diseases 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 230000007574 infarction Effects 0.000 description 22
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 21
- 206010030113 Oedema Diseases 0.000 description 21
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 21
- 230000004083 survival effect Effects 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 240000007164 Salvia officinalis Species 0.000 description 19
- 208000001435 Thromboembolism Diseases 0.000 description 19
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 206010002660 Anoxia Diseases 0.000 description 17
- 241000976983 Anoxia Species 0.000 description 17
- 108010025020 Nerve Growth Factor Proteins 0.000 description 17
- 230000007953 anoxia Effects 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 17
- 230000002879 macerating effect Effects 0.000 description 17
- 239000002858 neurotransmitter agent Substances 0.000 description 17
- 230000002980 postoperative effect Effects 0.000 description 17
- -1 tanshinone compound Chemical class 0.000 description 17
- 241000521257 Hydrops Species 0.000 description 16
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 16
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 16
- 230000008499 blood brain barrier function Effects 0.000 description 16
- 210000001218 blood-brain barrier Anatomy 0.000 description 16
- 208000026106 cerebrovascular disease Diseases 0.000 description 16
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 238000011084 recovery Methods 0.000 description 16
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- 229960005356 urokinase Drugs 0.000 description 16
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 15
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 15
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 14
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 14
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 210000000269 carotid artery external Anatomy 0.000 description 14
- 210000003657 middle cerebral artery Anatomy 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 230000006735 deficit Effects 0.000 description 13
- 206010002091 Anaesthesia Diseases 0.000 description 12
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 12
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 12
- 102000015336 Nerve Growth Factor Human genes 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 12
- 230000037005 anaesthesia Effects 0.000 description 12
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 12
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- 230000037149 energy metabolism Effects 0.000 description 11
- 230000001976 improved effect Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 230000009223 neuronal apoptosis Effects 0.000 description 11
- 239000012188 paraffin wax Substances 0.000 description 11
- 230000010412 perfusion Effects 0.000 description 11
- 230000000630 rising effect Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000001964 calcium overload Effects 0.000 description 10
- 210000001168 carotid artery common Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 9
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 9
- 102100029268 Neurotrophin-3 Human genes 0.000 description 9
- 229930040373 Paraformaldehyde Natural products 0.000 description 9
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 9
- 239000003463 adsorbent Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 230000003511 endothelial effect Effects 0.000 description 9
- 230000002461 excitatory amino acid Effects 0.000 description 9
- 239000003257 excitatory amino acid Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 229940053128 nerve growth factor Drugs 0.000 description 9
- 229920002866 paraformaldehyde Polymers 0.000 description 9
- 229960002275 pentobarbital sodium Drugs 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 230000003248 secreting effect Effects 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- 206010028851 Necrosis Diseases 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 210000004004 carotid artery internal Anatomy 0.000 description 8
- 229960003638 dopamine Drugs 0.000 description 8
- 238000004043 dyeing Methods 0.000 description 8
- 238000011049 filling Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 210000004088 microvessel Anatomy 0.000 description 8
- 230000017074 necrotic cell death Effects 0.000 description 8
- 210000000653 nervous system Anatomy 0.000 description 8
- 230000003188 neurobehavioral effect Effects 0.000 description 8
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 8
- 229960002748 norepinephrine Drugs 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 230000035699 permeability Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000001732 thrombotic effect Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 102000007072 Nerve Growth Factors Human genes 0.000 description 7
- 210000000683 abdominal cavity Anatomy 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 7
- 210000003710 cerebral cortex Anatomy 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000016273 neuron death Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 230000002537 thrombolytic effect Effects 0.000 description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 description 6
- 206010069729 Collateral circulation Diseases 0.000 description 6
- 108050009340 Endothelin Proteins 0.000 description 6
- 102000002045 Endothelin Human genes 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- 230000002146 bilateral effect Effects 0.000 description 6
- 230000036770 blood supply Effects 0.000 description 6
- 210000004958 brain cell Anatomy 0.000 description 6
- 208000029028 brain injury Diseases 0.000 description 6
- 230000003727 cerebral blood flow Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 208000037906 ischaemic injury Diseases 0.000 description 6
- QERVEQIRMVEYBB-UHFFFAOYSA-N methyl acetate;pentane Chemical compound CCCCC.COC(C)=O QERVEQIRMVEYBB-UHFFFAOYSA-N 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 230000000324 neuroprotective effect Effects 0.000 description 6
- 239000003900 neurotrophic factor Substances 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000001131 transforming effect Effects 0.000 description 6
- 210000003556 vascular endothelial cell Anatomy 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 206010048962 Brain oedema Diseases 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 5
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical class C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 208000006752 brain edema Diseases 0.000 description 5
- 201000008247 brain infarction Diseases 0.000 description 5
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 210000003194 forelimb Anatomy 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 5
- 229940096397 interleukin-8 Drugs 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 150000002978 peroxides Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 201000003099 Renovascular Hypertension Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 206010047249 Venous thrombosis Diseases 0.000 description 4
- 239000003282 amino acid receptor affecting agent Substances 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 210000002565 arteriole Anatomy 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 4
- 210000003725 endotheliocyte Anatomy 0.000 description 4
- 230000002964 excitative effect Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000019581 neuron apoptotic process Effects 0.000 description 4
- 230000006576 neuronal survival Effects 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000000250 revascularization Effects 0.000 description 4
- 210000001202 rhombencephalon Anatomy 0.000 description 4
- 229930183842 salvianolic acid Natural products 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 210000001627 cerebral artery Anatomy 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 235000019353 potassium silicate Nutrition 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 208000037823 Cerebral ischemia/reperfusion injury Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- 206010014522 Embolism venous Diseases 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 108091006088 activator proteins Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000028600 axonogenesis Effects 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000008344 brain blood flow Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 2
- 229950004794 dizocilpine Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229950002798 enlimomab Drugs 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- QVDYYQXUNAQSNI-UHFFFAOYSA-N ethyl acetate;pentane Chemical compound CCCCC.CCOC(C)=O QVDYYQXUNAQSNI-UHFFFAOYSA-N 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 208000004043 venous thromboembolism Diseases 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- UJZQBMQZMKFSRV-RGKBJLTCSA-N (2s,3s)-4-[(e)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 UJZQBMQZMKFSRV-RGKBJLTCSA-N 0.000 description 1
- IJAGKEKOJGWANE-KCBWXHRDSA-N (3r,4r,5r)-5-[(2s,3r)-4-[(e)-2-carboxyethenyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carbonyl]oxy-3,4-dihydroxycyclohexene-1-carboxylic acid Chemical compound O[C@@H]1[C@H](O)C=C(C(O)=O)C[C@H]1OC(=O)[C@@H]1C(C(\C=C\C(O)=O)=CC=C2O)=C2O[C@@H]1C1=CC=C(O)C(O)=C1 IJAGKEKOJGWANE-KCBWXHRDSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 241000272165 Charadriidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 206010051078 Lacunar infarction Diseases 0.000 description 1
- UJZQBMQZMKFSRV-PHQFMFTGSA-N Lithospermic acid Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1c2[C@@H](C(=O)O)[C@H](c3cc(O)c(O)cc3)Oc2c(O)cc1 UJZQBMQZMKFSRV-PHQFMFTGSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- NFOCYHUCMXEHDG-UHFFFAOYSA-N Monomethyl lithospermate Natural products COC(=O)C1C(C=2C=C(O)C(O)=CC=2)OC(C(=CC=2)O)=C1C=2C=CC(=O)OC(C(O)=O)CC1=CC=C(O)C(O)=C1 NFOCYHUCMXEHDG-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 241000294142 Vascellum Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000003818 area postrema Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical group O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- OZFSWVOEXHGDES-INIZCTEOSA-N lubeluzole Chemical compound C([C@@H](O)CN1CCC(CC1)N(C)C=1SC2=CC=CC=C2N=1)OC1=CC=C(F)C(F)=C1 OZFSWVOEXHGDES-INIZCTEOSA-N 0.000 description 1
- 229950009851 lubeluzole Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000003977 optic chiasm Anatomy 0.000 description 1
- 230000004413 optic chiasma Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000008886 xiangdan Substances 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210489121.8A CN103083297B (zh) | 2012-11-20 | 2012-11-20 | 丹酚酸a组合物用于制备改善脑缺血后的神经功能症状药物的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210489121.8A CN103083297B (zh) | 2012-11-20 | 2012-11-20 | 丹酚酸a组合物用于制备改善脑缺血后的神经功能症状药物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103083297A true CN103083297A (zh) | 2013-05-08 |
CN103083297B CN103083297B (zh) | 2015-11-25 |
Family
ID=48196782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210489121.8A Active CN103083297B (zh) | 2012-11-20 | 2012-11-20 | 丹酚酸a组合物用于制备改善脑缺血后的神经功能症状药物的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103083297B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083296A (zh) * | 2012-11-20 | 2013-05-08 | 蒋春红 | 丹酚酸a组合物用于制备保护脑血管内皮细胞药物的用途 |
CN103083298A (zh) * | 2012-11-20 | 2013-05-08 | 蒋春红 | 丹酚酸a组合物用于制备保护缺血脑组织损伤药物的用途 |
CN109985033A (zh) * | 2017-12-29 | 2019-07-09 | 中国医学科学院药物研究所 | 丹酚酸c在制备抗脑卒中药物中的应用 |
CN110361242A (zh) * | 2019-08-14 | 2019-10-22 | 武汉赛维尔生物科技有限公司 | 一种用于眼球组织的固定液以及眼球组织制片的预处理方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1378837A (zh) * | 2001-04-09 | 2002-11-13 | 中国医学科学院药物研究所 | 丹参丹酚酸类化合物在制药中的应用 |
CN100999470A (zh) * | 2006-11-17 | 2007-07-18 | 北京本草天源药物研究院 | 一种丹参丹酚酸a及制剂的制备方法和用途 |
CN101186572A (zh) * | 2007-12-19 | 2008-05-28 | 天津大学 | 从丹参水提取液中一步分离纯化丹酚酸的方法 |
CN101433583A (zh) * | 2007-11-16 | 2009-05-20 | 上海雷允上科技发展有限公司 | 一种丹参组合物及其制备方法和检测方法以及应用 |
CN102212004A (zh) * | 2010-04-06 | 2011-10-12 | 山东靶点药物研究有限公司 | 一种催化转化丹酚酸b制备丹酚酸a的方法 |
CN103083298A (zh) * | 2012-11-20 | 2013-05-08 | 蒋春红 | 丹酚酸a组合物用于制备保护缺血脑组织损伤药物的用途 |
CN103083296A (zh) * | 2012-11-20 | 2013-05-08 | 蒋春红 | 丹酚酸a组合物用于制备保护脑血管内皮细胞药物的用途 |
CN103083301A (zh) * | 2012-11-20 | 2013-05-08 | 蒋春红 | 丹酚酸a组合物用于制备预防和或治疗脑血栓药物的用途 |
CN103099802A (zh) * | 2012-11-20 | 2013-05-15 | 蒋春红 | 丹酚酸a组合物用于制备挽救缺血半暗带药物的用途 |
CN103142577A (zh) * | 2012-11-20 | 2013-06-12 | 陈飞虹 | 一种丹酚酸a组合物及其制备药物用途 |
-
2012
- 2012-11-20 CN CN201210489121.8A patent/CN103083297B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1378837A (zh) * | 2001-04-09 | 2002-11-13 | 中国医学科学院药物研究所 | 丹参丹酚酸类化合物在制药中的应用 |
CN100999470A (zh) * | 2006-11-17 | 2007-07-18 | 北京本草天源药物研究院 | 一种丹参丹酚酸a及制剂的制备方法和用途 |
CN101433583A (zh) * | 2007-11-16 | 2009-05-20 | 上海雷允上科技发展有限公司 | 一种丹参组合物及其制备方法和检测方法以及应用 |
CN101186572A (zh) * | 2007-12-19 | 2008-05-28 | 天津大学 | 从丹参水提取液中一步分离纯化丹酚酸的方法 |
CN102212004A (zh) * | 2010-04-06 | 2011-10-12 | 山东靶点药物研究有限公司 | 一种催化转化丹酚酸b制备丹酚酸a的方法 |
CN103083298A (zh) * | 2012-11-20 | 2013-05-08 | 蒋春红 | 丹酚酸a组合物用于制备保护缺血脑组织损伤药物的用途 |
CN103083296A (zh) * | 2012-11-20 | 2013-05-08 | 蒋春红 | 丹酚酸a组合物用于制备保护脑血管内皮细胞药物的用途 |
CN103083301A (zh) * | 2012-11-20 | 2013-05-08 | 蒋春红 | 丹酚酸a组合物用于制备预防和或治疗脑血栓药物的用途 |
CN103099802A (zh) * | 2012-11-20 | 2013-05-15 | 蒋春红 | 丹酚酸a组合物用于制备挽救缺血半暗带药物的用途 |
CN103142577A (zh) * | 2012-11-20 | 2013-06-12 | 陈飞虹 | 一种丹酚酸a组合物及其制备药物用途 |
Non-Patent Citations (1)
Title |
---|
王颖等: "高温高压下丹酚酸B,紫草酸水溶液化学变化的研究", 《中国中药杂志》, vol. 36, no. 4, 28 February 2011 (2011-02-28), pages 434 - 438 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083296A (zh) * | 2012-11-20 | 2013-05-08 | 蒋春红 | 丹酚酸a组合物用于制备保护脑血管内皮细胞药物的用途 |
CN103083298A (zh) * | 2012-11-20 | 2013-05-08 | 蒋春红 | 丹酚酸a组合物用于制备保护缺血脑组织损伤药物的用途 |
CN109985033A (zh) * | 2017-12-29 | 2019-07-09 | 中国医学科学院药物研究所 | 丹酚酸c在制备抗脑卒中药物中的应用 |
CN110361242A (zh) * | 2019-08-14 | 2019-10-22 | 武汉赛维尔生物科技有限公司 | 一种用于眼球组织的固定液以及眼球组织制片的预处理方法 |
CN110361242B (zh) * | 2019-08-14 | 2022-01-18 | 武汉赛维尔生物科技有限公司 | 一种用于眼球组织的固定液以及眼球组织制片的预处理方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103083297B (zh) | 2015-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103083297B (zh) | 丹酚酸a组合物用于制备改善脑缺血后的神经功能症状药物的用途 | |
CN103083303B (zh) | 丹酚酸a组合物用于制备改善脑缺血后的神经功能症状药物的用途 | |
CN103099802B (zh) | 丹酚酸a组合物用于制备挽救缺血半暗带药物的用途 | |
CN103083301B (zh) | 丹酚酸a组合物用于制备预防和或治疗脑血栓药物的用途 | |
CN103083298B (zh) | 丹酚酸a组合物用于制备保护缺血脑组织损伤药物的用途 | |
CN103083304B (zh) | 丹酚酸a组合物用于制备预防和/或治疗脑血栓药物的用途 | |
CN103083302A (zh) | 丹酚酸a组合物用于制备保护缺血脑组织损伤药物的用途 | |
CN103083306A (zh) | 丹酚酸a组合物用于制备抑制脑组织神经元损伤或死亡药物的用途 | |
CN103083296B (zh) | 丹酚酸a组合物用于制备保护脑血管内皮细胞药物的用途 | |
CN103142573A (zh) | 丹酚酸a冻干粉针用于制备改善脑缺血后的神经功能症状药物的用途 | |
CN103142575A (zh) | 丹酚酸a冻干粉针用于制备抑制脑组织神经元损伤或死亡药物的用途 | |
CN103142542A (zh) | 一种丹酚酸a胶囊剂及其制备药物用途 | |
CN103301104B (zh) | 丹酚酸a组合物用于制备挽救缺血半暗带药物的用途 | |
CN103083257A (zh) | 一种丹酚酸a冻干粉针及其制备药物用途 | |
CN103083299B (zh) | 一种丹酚酸a组合物及其制备药物用途 | |
CN103142517A (zh) | 一种丹酚酸a滴丸剂及其制备药物用途 | |
CN103006580B (zh) | 丹酚酸a冻干粉针用于制备预防和/或治疗脑血栓药物的用途 | |
CN103006578B (zh) | 丹酚酸a冻干粉针用于制备改善脑缺血后的神经功能症状药物的用途 | |
CN103432110A (zh) | 丹酚酸a冻干粉针用于制备挽救缺血半暗带药物的用途 | |
CN103142576A (zh) | 丹酚酸a冻干粉针用于制备保护脑血管内皮细胞药物的用途 | |
CN103142574A (zh) | 一种丹酚酸a冻干粉针及其制备药物用途 | |
CN103006581B (zh) | 丹酚酸a冻干粉针用于制备挽救缺血半暗带药物的用途 | |
CN103006579B (zh) | 丹酚酸a冻干粉针用于制备保护脑血管内皮细胞药物的用途 | |
CN103083305B (zh) | 一种丹酚酸a组合物及其制备药物用途 | |
CN103120649A (zh) | 丹酚酸a冻干粉针用于制备抑制脑组织神经元损伤或死亡药物的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Jiang Chunhong Document name: the First Notification of an Office Action |
|
CB02 | Change of applicant information |
Address after: 100011 Beijing City, Xicheng District Street No. 23 Hospital Building No. 7 room 1804 sunshine King Applicant after: Jiang Chunhong Address before: 100011 Beijing City, Xicheng District Street No. 23 Hospital of Sun King Room 1804 North Applicant before: Jiang Chunhong |
|
CB02 | Change of applicant information | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 100027 Beijing city Chaoyang District Xinyuanli No. 16 Kun Sha center 3 room 902 Applicant after: Jiang Chunhong Address before: 100011 Beijing City, Xicheng District Street No. 23 Hospital Building No. 7 room 1804 sunshine King Applicant before: Jiang Chunhong |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151009 Address after: 341000 East Road, Shahe Industrial Park, Jiangxi, Ganzhou, No. 8 Applicant after: Jiangxi Qingfeng Pharmaceutical Co., Ltd. Address before: 100027 Beijing city Chaoyang District Xinyuanli No. 16 Kun Sha center 3 room 902 Applicant before: Jiang Chunhong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |